Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive December 1, 2011	UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity.
Pharmaceutical Executive January 1, 2007 Sarah Houlton	Global Report: No Satisfaction Germans on both sides of the political spectrum agree that their country's healthcare system needs reform. The latest attempt at change, though, doesn't really meet either side's needs.
Pharmaceutical Executive June 1, 2012	Europe Responds to Medical Device 'Crisis' A recent medical device controversy in France has pushed European health ministers to agree on a crisis management program for the troubled sector.
Pharmaceutical Executive June 1, 2014 O'Connor et al.	Challenges to the Specialty Business Model New constraints require new solutions. Innovative, value-based pricing models will be critical to securing reimbursement and continued market access of high-price drugs.
Pharmaceutical Executive April 1, 2011	How US Health Reform Is Hitting Canada Canada's Russell Williams, of Rx&D, talks about the impact of US health reform on his role as chief spokesman for the country's R&D industry.
Chemistry World August 23, 2012 Simon Campbell	Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth.
Pharmaceutical Executive August 1, 2012 Carol Ann Williams	Data Exclusivity: Making the Case As the scope and complexity of registration information demanded by regulators increases, protection of that know-how has become a critical differentiator in the "go" or "no go" calculation on whether to invest in a new medicine.
Pharmaceutical Executive May 1, 2007 Humphrey Taylor	Commentary: The Sky is Falling! Healthcare systems in the developed world are in crisis. A permanent one. Patients and their physicians will always want more treatments than governments or employers are willing to pay for.
Pharmaceutical Executive August 1, 2008 Sarah Houlton	Jumping the Gun The Association of the British Pharmaceutical Industry and the British government have come up with a solution for price regulation that isn't as bad as the industry had feared.
Pharmaceutical Executive August 1, 2014	EFPIA's 'Integrated Strategy' in Europe: Out of the Frying Pan, Into the Fire? Industry's grand vision for reshaping the life sciences in Europe may ultimately prove to be a lost cause.
Pharmaceutical Executive October 1, 2010	Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector.
Pharmaceutical Executive January 1, 2011	The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade.
Pharmaceutical Executive May 1, 2011 Julian Upton	UK Stakeholders Have Their Say on Value-Based Pricing The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance.
Pharmaceutical Executive October 1, 2010	When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve?
Chemistry World July 10, 2012	Interview: EMA head Guido Rasi His five-year appointment comes during a period of dramatic change for the pharma industry, which is struggling with patent expirations for many of its biggest selling drugs and a paucity of new drugs coming through the pipeline to take their place.
Pharmaceutical Executive June 1, 2011	Are You Ready for the New China? The ability to act as a good corporate citizen and assert a useful role in national industrial policy on health is going to be essential to success in the new China.
Chemistry World February 6, 2014 Patrick Walter	Clouds on the horizon for UK science The UK needs to up its game to keep up with the rest of the continent when it comes to science, Europe's research chief has said.
Pharmaceutical Executive November 1, 2011	Does a German Launch Make Sense? Will the structure and ambiguity of Germany's new medicines pricing system bring a halt to new drug launches in Europe's largest market?
Pharmaceutical Executive January 21, 2014 Comer & Upton	Pharm Exec's Annual Industry Outlook 2014 For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive; muddling through is so yesterday.
Pharmaceutical Executive February 1, 2007 Sarah Houlton	Global Report: Under One Roof The UK government is planning to set up a single body to oversee all health research in universities and hospitals - and to facilitate partnerships between government agencies and industry.
Pharmaceutical Executive April 1, 2014	Whatever Happened To Faster Reimbursement For Generics In Europe? The plan to accelerate generic pricing and reimbursement has become another tragic European casualty.
Pharmaceutical Executive October 1, 2006 Sarah Houlton	Global Report: Please Come Back Health authorities in Europe are working hard to reestablish their countries as preferred locations for pharma's R&D facilities. Fortunately, they've got a blueprint: China.
Chemistry World February 17, 2012 Ned Stafford	EU Innovation Position Slipping The growth of innovation in the EU is slowing, making it more difficult for the EU to close the gap with the global leaders for innovation.
Chemistry World May 9, 2008 Richard Van Noorden	Blueprint for 1bn UK technology drive unveiled The UK's Technology Strategy Board (TSB) has outlined how it will invest 1 billion over the next three years to boost innovative R&D and business.
Pharmaceutical Executive July 1, 2011	Holy Surge of Enthusiasm! While Europe's EFPIA preaches about embracing change, much remains to be done to prove the adjustment in philosophy.
Pharmaceutical Executive May 1, 2012	Value-Based Pricing: Too High a Price for UK Pharma? Changes to the system in the UK could finally put some real metrics behind the elusive concept of value but with payers clearly in the driver's seat, who needs clarity?
Chemistry World October 29, 2007 Arthur Rogers	Deal to Allow Poor Nations Better Access to Cheap Drugs MEPs belatedly approved EU ratification of a 2005 World Trade Organization protocol on compulsory licensing -- potentially paving the way for developing countries to order generic drugs from manufacturers abroad without infringing patent rights.
Pharmaceutical Executive May 1, 2005 Sarah Houlton	Global Report: Iron Fist The United Kingdom is hardening its stance on pharma industry issues.
Pharmaceutical Executive December 1, 2010 Zhu Shen	China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda
Knowledge@Wharton	Analyzing Brand-name and Generic Drug Costs in the U.S. and Eight Other Countries A new study comparing average prices for pharmaceuticals in nine countries -- the US, Canada, Chile, France, Germany, Italy, Japan, Mexico and the UK -- shows that average prices are highest in Japan, while prices in other countries are between 6% and 33% lower than prices in the US.
Chemistry World January 7, 2013 Andrew Turley	Wellcome Trust launches investment wing The Wellcome Trust has provided 200 million pounds to launch an investment company that aims to support innovative healthcare businesses with the potential to transform the markets in which they operate.
Chemistry World March 4, 2013 Andy Extance	UK considers patent rule change for trials The UK has announced plans to amend aspects of its patent law that may be encouraging pharma companies to run their clinical trials in other countries.
Pharmaceutical Executive October 1, 2014	Eruptions on the Drug-Pricing Horizon in Europe An escalating political debate over pharma pricing and reimbursement nears the boiling point.
Chemistry World June 28, 2013 Helen Carmichael	European research funding deal on the Horizon The informal accord, reached on 25 June, just days before the end of the Irish presidency of the EU, offers a helping hand to scientists from poorer member states, in an attempt to balance the program's 'focus on excellence.'
Pharmaceutical Executive July 1, 2012	Country Report: Thailand Indochina's biggest pharmaceutical market has quickly matured over the past years due to the implementation of heavy cost containment measures meant to make healthcare more accessible to the patient.
Pharmaceutical Executive October 1, 2011	Sweden: Setting the Pace for Global Pharma On health system decentralization, regulatory convergence, drug detailing, promotion, patient information, the environment, value-based pricing, and the pursuit of cost-effectiveness, the Nordics have been true innovators over the past decades.
Knowledge@Wharton August 27, 2003	Code Blue: Combating Rising Healthcare Costs Calls for Strong Medicine It's been said many times over that the U.S. healthcare industry is a sick patient in search of a cure. The metaphor is a grim reflection of how the country is coping with an aging population, rising costs and an inefficient healthcare delivery system.
Chemistry World August 17, 2015 Anthony King	Greek crisis puts pressure on pharmaceuticals Supplies of critical drugs to Greek pharmacies have become sparse and erratic as the economic crisis squeezes public spending
Pharmaceutical Executive October 1, 2011	Regulation and Reputation: Still Two Solitudes The pharmaceutical and biopharmaceutical industries will only be able to continue providing patients with safe and effective medicines if the price is affordable. This will involve changes in attitudes by the industry, regulators, politicians, and the public.
Chemistry World July 25, 2012	Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population.
Pharmaceutical Executive June 1, 2011	A Lack of Information Why has the EU still not managed to update its rules on information about medicines?
Pharmaceutical Executive June 1, 2014	Hopes High as EU Heads Into Leadership Change The principal drug industry associations in Europe launched a call in mid-May for "an integrated European industrial policy for the pharmaceuticals sector."
Chemistry World September 2007 Ian Pearson	Comment: Global Science Matters The UK's new science minister says that an international perspective is vital for scientific growth.
Pharmaceutical Executive July 3, 2007 Humphrey Taylor	Opinion: Lead, Follow, or Get Out of the Way A comparative-effectiveness board is coming. The pharmaceutical industry's wise will embrace the change.
Pharmaceutical Executive April 1, 2009 Jill Wechsler	Kickoff for Reform In addition to overhauling healthcare, Congress is weighing proposals for updating FDA policies and expanding access to drugs.
Chemistry World May 8, 2008 Hepeng Jia	China to fast track pioneering drugs China is to speed up the approval of groundbreaking new drugs in an effort to encourage innovation in its pharmaceutical sector, a State Food and Drug Administration (SFDA) official has revealed.
Chemistry World December 21, 2009 Ned Stafford	French researchers get funding boost French President Nicolas Sarkozy caught the Christmas spirit early this year, announcing plans to increase spending by 35 billion Euros to boost the nation's scientific and technological competitiveness.
Pharmaceutical Executive December 1, 2008 Jill Wechsler	Challenge and Challenges Expanded healthcare coverage also fits the goals of pharma manufacturers.
Pharmaceutical Executive July 1, 2009	The Pharmerging Future A guide to grabbing growth in seven "pharmerging" markets.
Pharmaceutical Executive September 1, 2010	Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development.